VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript
- VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript
- 03/26/2024
|
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
- Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
- 03/25/2024
|
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
- Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
- 03/21/2024
|
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
- HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems"), a leading veterinary diagnostic laboratory service, to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan.
- 03/20/2024
|
Volition appoints Dr Andrew Retter as Chief Medical Officer
- HENDERSON, Nev. , March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
- 03/19/2024
|
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
- HENDERSON, Nev. , Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.
- 02/02/2024
|
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
- The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.
- 01/18/2024
|
VolitionRx has 'compelling plans' to advance veterinary care in 2024
- VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.
- 01/04/2024
|
Volition Issues Business Review 2023
- HENDERSON, Nev. , Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.
- 01/04/2024
|
Volition secures €5M in financing from Belgium's Wallonie Entreprendre
- VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective introduction of the diagnostic solution into clinical practice.
- 12/05/2023
|
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
- HENDERSON, Nev. , Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A.
- 12/05/2023
|
VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript
- VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Tim Moore - EF Operator Good morning, ladies and gentlemen. Thank you for standing by.
- 11/15/2023
|
VolitionRx's Nu.Q Vet Cancer Test sees five-fold revenue surge in 2023
- VolitionRx (NYSE-A:VNRX) said its Nu.Q Vet Cancer Test revenue has seen a nearly five-fold increase in sales over the first nine months of 2023 compared to the same period last year. The Nu.Q test involves analyzing nucleosomes, which are structural units of DNA, to identify specific patterns or changes associated with the presence of cancer in animals.
- 11/14/2023
|
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
- Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
- 11/14/2023
|
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
- Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
- 11/08/2023
|
VolitionRx joins up with VPG to launch Nu.Q Vet Cancer Test in UK and Ireland
- VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland. The NuQ Vet Cancer Test is a groundbreaking tool for the early detection and monitoring of cancer in dogs and VPG will be the first-to-market diagnostics laboratory in the UK to offer the test, the company said.
- 11/06/2023
|
VolitionRx highlights study demonstrating Nu.Q NETs is promising biomarker for septic shock
- VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and it could play a vital role in sepsis prognosis. The paper is about a 150-patient study led by Professor Guillaume Monneret, Head of Clinical Immunology Laboratory at Hospices Civils de Lyon in France.
- 10/19/2023
|
VolitionRx welcomes US Ambassador to Belgium for exclusive tour of research facilities
- VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to the Kingdom of Belgium, for an exclusive tour of its state-of-the-art research, development, and manufacturing facilities located in Isnes, Belgium. "Ambassador Adler's visit today was an ideal opportunity for us to celebrate this collaborative work and highlight the close ties we have fostered between US and Belgian stakeholders over the last 13 years,” Gaetan Michel, Volition's COO said in a statement.
- 10/18/2023
|
VolitionRx to present cancer detection abstracts at European oncology conference
- VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection tools at the annual congress of the European Society for Medical Oncology (ESMO) 2023. "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma and introduce what we believe to be an entirely new method for the detection of cancer,” Volition's chief scientific officer Dr. Jake Micallef said in a statement.
- 10/16/2023
|
VolitionRx holds roundtable on sepsis management
- VolitionRx (NYSE-A:VNRX) has revealed insights from a recent Key Opinion Leader (KOL) roundtable focused on sepsis management. The KOL roundtable brought together a panel of leading experts in sepsis to discuss the potential of leveraging Volition's Nu.Q NETs technology in clinical practice.
- 10/13/2023
|
VolitionRx to unveil new cancer detection method insights at upcoming webinar
- VolitionRx (NYSE-A:VNRX) Limited has announced that it is participating in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 at ESMO 2023, the annual congress of the European Society for Medical Oncology. The multi-national epigenetics company said the webinar will take place on Thursday, October 26 at 10:30 AM EDT and will include updates from Volition's chief scientific officer Dr Jake Micallef, its chief commercial officer Gael Forterre, as well as Dr Andrew Retter, a leading UK-based haematologist and medical consultant at Volition.
- 10/02/2023
|
VolitionRx to host sepsis management roundtable
- VolitionRx (NYSE-A:VNRX) said it is hosting a roundtable discussion in Athens this weekend which will bring together world-renowned experts in sepsis, a life-threatening condition that occurs in response to an infection. The company said the roundtable, chaired by Professor of Medicine at University Paris Saclay-UVSQ Djillali Annane, will cover the challenges of sepsis, the link between Neutrophil Extracellular Traps (NETs) and sepsis and how Volition's Nu.Q NETs technology could potentially be used effectively in clinical practice.
- 09/13/2023
|
VolitionRx Limited (VNRX) Q2 2023 Earnings Call Transcript
- VolitionRx Limited (NYSE:VNRX ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - Founder, CEO, President and Director Terig Hughes - CFO & Treasurer Tom Butera - CEO, Volition Veterinary Diagnostics Development LLC Conference Call Participants Bruce Jackson - Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by.
- 08/15/2023
|
VolitionRx Limited prices major public offering to fund research and product development
- VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million. The epigenetics company plans to offer 13 million shares at $1.27 per share.
- 06/01/2023
|
VolitionRx reports cash and cash equivalents of $10M at 1Q-end
- VolitionRx (NYSE-A:VNRX) Limited said it had cash and cash equivalents of around $10 million as of March 31, 2023, as it announced financial results and a business update for the first quarter. The company said it received approximately $8 million through an underwritten public offering of its common stock in February, adding that it expects to receive a further $13 million in milestone payments from Heska Corporation and additional funding from three Belgian agencies over the coming months.
- 05/11/2023
|
VolitionRx posts 240% rise in 2022 revenue; outlines upcoming milestones
- VolitionRx Limited (NYSE-A:VNRX) has reported a sharp rise in annual revenue as it ‘shifts gears' towards its goal of becoming a commercial company with products. The company, which is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals, recorded revenue of approximately $300,000 for the year to December 31, 2022, up 240% over the prior year.
- 03/16/2023
|
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
- Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev.
- 03/10/2023
|
VolitionRx reveals pricing of its $7.5M public equity offering
- VolitionRx (NYSE-A:VNRX) Limited announced that it has priced its underwritten public offering of 4.3 million company common shares at $1.75 per share, with expected gross proceeds to Volition of $7.525 million. The multi-national epigenetics company said it intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
- 02/17/2023
|
Why Is VolitionRX (VNRX) Stock Down 17% Today?
- VolitionRX (NYSEMKT: VNRX ) stock is taking a beating on Friday after the company revealed a proposed public offering for its shares. The big news here is VolitionRX planning a public offering of it VNRX stock.
- 02/17/2023
|
VolitionRx says Nu.Q Vet Cancer Test now available for pre-order at the point-of-care through Heska Corporation
- VolitionRx (NYSE-A:VNRX) has announced its Nu.Q Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation. The Henderson, Nevada-based multi-national epigenetics company said Heska's Nu.Q Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low-cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.
- 02/16/2023
|
VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory network
- VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory network in the US. The Henderson, Nevada-based multi-national epigenetics company noted that IDEXX is a global leader in pet healthcare innovation and is well-positioned to roll out the IDEXX Nu.Q Canine Cancer Screen worldwide.
- 01/12/2023
|
VolitionRx highlights 2022 achievements as it advances to commercial operations
- VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and development to one with commercial operations. Henderson, Nevada-based Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
- 01/09/2023
|
Penny Stocks To Buy: 6 Insider Picks Before 2023
- Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/21/2022
|
3 Top Penny Stocks To Buy According To Insiders Before 2023
- Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2022
|
VolitionRx Limited (VNRX) Q3 2022 Earnings Call Transcript
- VolitionRx Limited (NYSE:VNRX ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - Founder, Group CEO Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Michael Okunewitch - Maxim Group Bruce Jackson - The Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by.
- 11/15/2022
|
VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening company
- VolitionRx (NYSE-A:VNRX) said it ended third-quarter 2022 with US$16.4 million in cash and cash equivalents, thanks to careful management of expenditures with net cash used in operating activities averaging approximately $2.3 million per month in the quarter. Cash equivalents was down slightly from $16.7 million at the quarter ended June 30, 2022, the Henderson, Nevada-based company said.
- 11/15/2022
|
VolitionRx teams up with leading French veterinary group to assess potential of cancer screening technology
- VolitionRx (NYSE-A:VNRX) Limited said it will work with a renowned French veterinary referral clinic to further assess the potential of its cancer screening technology in dogs and cats. A non-interventional study of Volition's Nu.Q Vet Cancer Test will be overseen by Dr Jérôme Benoit, the clinical director of Oncovet in Lille.
- 11/14/2022
|
VolitionRX inks global agreement to provide Nu.Q cancer detection test to veterinarians
- VolitionRx (NYSE-A:VNRX) said it has signed a global agreement with a market leader in pet healthcare to supply its Nu.Q Vet Cancer Test to veterinarians. According to VolitionRx (NYSE-A:VNRX), there are approximately 84 million pet dogs in the US.
- 10/20/2022
|
VolitionRx adds marketing executive Mickie Henshall to its board of directors
- VolitionRx (NYSE-A:VNRX) Limited said it has appointed veteran marketing executive Mickie Henshall to its board of directors. The company noted that Henshall has over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries.
- 08/16/2022
|
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2022 Results - Earnings Call Transcript
- VolitionRx Limited (NYSE:VNRX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Nathan Weinstein - Aegis Capital Steven Ralston - Zacks Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited's Second Quarter '22 Earnings Conference Call.
- 08/13/2022
|
VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization efforts
- VolitionRx (NYSE-A:VNRX) Limited ended the second quarter with $16.7 million in the bank to help advance research and commercialization efforts for its Nucleosomics platform for blood tests. The Henderson, Nevada-based epigenetics company had a busy quarter that saw it receive a CE Mark for its Nu.Q Netosis (NETs) test in Europe and reveal new clinical studies for NETs in the US.
- 08/10/2022
|
VolitionRx to participate in US clinical study for NETs in sepsis cancer patients
- VolitionRx (NYSE-A:VNRX) Limited has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (NETs) in cancer patients with sepsis. The diagnostics and monitoring company said the trial will use Volition's Nu.Q NETs test for the study, which was Conformitè Europëenne (CE) marked earlier this year for the detection and evaluation of NETosis.
- 08/10/2022
|
VolitionRx appoints DXOCRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the US
- VolitionRx (NYSE-A:VNRX) Limited said it has appointed Diagnostic Oncology CRO, LLC (DXOCRO) to undertake development and clinical validation studies for its Nu.Q product portfolio in the US. The diagnostics and monitoring company said DXOCRO will conduct large-scale finding studies across multiple sites in the US using Volition's Nu.Q NETs and Nu.Q Cancer tests to determine clinical utility in sepsis and cancer.
- 08/08/2022
|
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
- VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
- 08/02/2022
|
VolitionRx announces pricing of underwritten public offering of 3 million shares at a public offering price of $2.00 each
- VolitionRx (NYSE-A:VNRX) Limited has announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million.
- 07/29/2022
|
VolitionRx presents data related to its NETs research at ISTH Congress
- VolitionRx (NYSE-A:VNRX) Limited announced it had presented data about its work on neutrophil extracellular traps, or NETs, at the International Society on Thrombosis and Haemostasis (ISTH) Congress. The firm, in collaboration with researchers at the University of Namur and QUALIblood in Belgium, published a poster presentation entitled "Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients" at the conference.
- 07/13/2022
|
VolitionRx says Nu.Q NETs test gets CE mark enabling clinical use in over 27 countries across Europe
- VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in over 27 countries across Europe. NETosis is a unique form of cell death characterized by the release of neutrophil extracellular traps, composed of decondensed chromatin, that trap and kill bacteria and viral particles.
- 05/31/2022
|
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q1 2022 Results - Earnings Call Transcript
- VolitionRx Limited (NYSE:VNRX ) Q1 2022 Results Conference Call May 12, 2022 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Tom Butera - Chief Executive Officer, Volition Veterinary Diagnostics Development Terig Hughes - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen. Thank you for standing by.
- 05/12/2022
|
VolitionRx reports strong 1Q anchored by $10M milestone payment from Heska for Nu.Q Vet Cancer Screening Test
- VolitionRx (NYSE-A:VNRX) Limited rounded out a strong first quarter by receiving a $10 million milestone payment from Heska Corporation for the company's Nu.Q Vet Cancer Screening Test. In exchange for granting Heska exclusive worldwide rights to sell the Nu.Q Vet Cancer Screening Test for companion animals, Volition has received a $10 million upfront payment and is eligible to receive up to a further $18 million based upon the achievement of near and mid-term milestones.
- 05/11/2022
|
VolitionRx launches its Nu.Q Vet Cancer Test in Asia through distributor SAGE Healthcare
- VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q Vet Cancer Test has been launched in Asia through SAGE Healthcare Private Limited, which was appointed as a non-exclusive licensee and distributor for the cancer test last year. Following pre-launch preparations, SAGE hosted a launch event featuring Professor Heather Wilson-Robles, chief medical officer at Volition Veterinary, and Dr Tom Butera, chief executive officer at Volition Veterinary on Friday, April 22.
- 04/25/2022
|
VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development process
- VolitionRx (NYSE-A:VNRX) Limited has announced the appointment of Sharon Ballesteros as the company's new US head of quality and development process. VolitionRx (NYSE-A:VNRX) said Ballesteros has more than 20 years of experience within the in-vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at companies such as Siemens Health Diagnostics, Thermo Fisher, and Agena Bioscience.
- 04/06/2022
|
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call Transcript
- VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test
- VolitionRx (NYSE-A:VNRX) Ltd has struck an exclusive $28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the former's Nu.Q vet cancer screening test at the point-of-care for pets. Heska will receive the worldwide rights to sell the test while VolitionRx (NYSE-A:VNRX) will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones.
- 03/29/2022
|
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
- Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m.
- 03/28/2022
|
VolitionRX: Cancer Diagnostic Tool For Our Best Friends
- VolitionRX develops and sells a simple and cost effective blood test to detect cancers and other serious diseases in our best friends, dogs.
- 12/20/2021
|
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
- AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update.
- 11/08/2021
|
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
- Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Published two clinical papers Continued focus on, and made strong progress towards, product launches and licensing in both the human and veterinary spaces worldwide AUSTIN, Texas, Aug. 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2021. Volition management will host a conference call tomorrow, August 12 at 8:00 a.m.
- 08/11/2021
|
VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
- AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2021, in addition to providing a business update.
- 08/04/2021
|
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
- AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading NHS Foundation Trusts on two studies in COVID-19 for which abstracts were released this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2021. Dr. Jake Micallef, Chief Scientific Officer of Volition said "We believe our Nu.Q® NETs assay will have wide applicability for monitoring diseases with a NETs component (such as COVID-19, sepsis, autoimmune diseases and cancer) and potentially to risk stratify patients for treatment selection.
- 07/22/2021
|
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
- Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Initiated production of product components at scale at the Company's Silver One facility Published three clinical papers Continued focus on product launches and licensing in both the human and veterinary spaces AUSTIN, Texas, May 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m.
- 05/11/2021
|
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
- AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in Scientific Reports of a paper entitled " A Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes ". Dr. Marielle Herzog, lead author of the paper and Volition's Research and Development Director, commented, "Our novel method detects and quantifies histone modifications present in the circulating nucleosomes in the blood of cancer patients.
- 03/31/2021
|
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
- AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment, effective May 1, 2021, of Dr. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition. "We are delighted that Tom has agreed to lead our Veterinary subsidiary.
- 03/30/2021
|
VolitionRx Limited Appoints Two New Directors
- AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. Kim Nguyen and Mr.
- 03/29/2021
|
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
- Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial for Non-Hodgkin's Lymphoma Expanded research program for the use of Nu.Q® technology in NETosis (COVID-19 and sepsis) Strengthened intellectual property portfolio Purchased and opened first production facility Strongest-ever cash position following a public offering in February 2021 AUSTIN, Texas, March 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2020. Volition management will host a conference call tomorrow, March 23 at 8:00 a.m.
- 03/22/2021
|
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
- AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a private company that has an abstract released today at the International Society for Apheresis meeting (e-ISFA), which is being held virtually this year. The poster presentation entitled "Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis" given by Dr. Andrew Aswani, Consultant in Intensive Care Medicine & Anesthesia at a leading London Hospital and Chief Medical Officer of Santersus AG, includes data showing that Nu.Q® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps ("NETs") in sepsis.
- 03/17/2021
|
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
- AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing a business update.
- 03/16/2021
|
Volition Has Released A Screening Test To Help Detect Early Stages Of Cancer In Dogs
- Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer diagnoses will continue to increase.
- 12/04/2020
|
VolitionRx Enters Commercial Stage
- VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death for dogs over ten years old.
- 12/02/2020
|
